MX2020012992A - Peptido con actividad antiobesidad y antidiabetica y usos del mismo. - Google Patents

Peptido con actividad antiobesidad y antidiabetica y usos del mismo.

Info

Publication number
MX2020012992A
MX2020012992A MX2020012992A MX2020012992A MX2020012992A MX 2020012992 A MX2020012992 A MX 2020012992A MX 2020012992 A MX2020012992 A MX 2020012992A MX 2020012992 A MX2020012992 A MX 2020012992A MX 2020012992 A MX2020012992 A MX 2020012992A
Authority
MX
Mexico
Prior art keywords
peptide
present
drugs
expression
peptide complex
Prior art date
Application number
MX2020012992A
Other languages
English (en)
Inventor
Yong Ji Chung
Eun Mi Kim
Original Assignee
Caregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caregen Co Ltd filed Critical Caregen Co Ltd
Publication of MX2020012992A publication Critical patent/MX2020012992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a un péptido y un complejo peptídico de la presente invención que presenta un efecto contra la obesidad al inhibir la acumulación de grasa y al descomponer la grasa ya acumulada, y que presenta un excelente efecto con respecto a la diabetes al reducir eficazmente el azúcar en sangre. El péptido y el complejo peptídico de la presente invención disminuyen la expresión de PPAR¿, ACC y aP2, los cuales son marcadores adipogénicos, incrementan la expresión de pHSL, AMPK-¿1, CGI-58 y ATGL, los cuales son factores lipolíticos y reducen el tamaño de las células grasas y los valores de colesterol en sangre. El péptido y el complejo peptídico de la presente invención, los cuales tienen excelente actividad e inocuidad se pueden aplicar ventajosamente a medicamentos y similares a medicamentos.
MX2020012992A 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo. MX2020012992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150059648A KR101669140B1 (ko) 2015-04-28 2015-04-28 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
PCT/KR2015/004749 WO2016175362A1 (ko) 2015-04-28 2015-05-12 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2020012992A true MX2020012992A (es) 2022-10-13

Family

ID=57198486

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2020012993A MX2020012993A (es) 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo.
MX2020012994A MX2020012994A (es) 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo.
MX2020012992A MX2020012992A (es) 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo.
MX2017013847A MX2017013847A (es) 2015-04-28 2015-05-12 Péptido con actividad antiobesidad y antidiabética y usos del mismo.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020012993A MX2020012993A (es) 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo.
MX2020012994A MX2020012994A (es) 2015-04-28 2015-05-12 Peptido con actividad antiobesidad y antidiabetica y usos del mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017013847A MX2017013847A (es) 2015-04-28 2015-05-12 Péptido con actividad antiobesidad y antidiabética y usos del mismo.

Country Status (22)

Country Link
US (4) US10351597B2 (es)
EP (4) EP3613760B1 (es)
JP (4) JP6606192B2 (es)
KR (1) KR101669140B1 (es)
CN (3) CN110105432B (es)
AU (4) AU2015393357B2 (es)
BR (4) BR122020019095B1 (es)
CA (4) CA2984287C (es)
CL (4) CL2017002718A1 (es)
CO (1) CO2017011998A2 (es)
EA (1) EA037799B1 (es)
ES (4) ES2831329T3 (es)
HK (1) HK1252251A1 (es)
IL (4) IL255263B (es)
MX (4) MX2020012993A (es)
MY (4) MY192154A (es)
NZ (4) NZ747392A (es)
PH (1) PH12017501983A1 (es)
SA (4) SA517390237B1 (es)
SG (4) SG10201913487RA (es)
WO (1) WO2016175362A1 (es)
ZA (1) ZA201708044B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR101887576B1 (ko) 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR101955511B1 (ko) * 2016-08-17 2019-03-11 (주)진셀팜 지방분해 촉진 효과를 가지는 펩타이드, 및 이의 용도
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102386705B1 (ko) * 2016-11-07 2022-04-21 주식회사 삼양사 알룰로스의 항비만 활성 관련 마커 유전자 및 이의 용도
CN106518971B (zh) * 2016-12-05 2019-12-10 华南理工大学 一种抗肥胖十肽canphelpnk
CN106749533B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖十七肽lnnpsvcdcdcmmkaar
CN106699846B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖十一肽nalkcchscpa
CN106749524B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖七肽npvwkrk
JP7133982B2 (ja) * 2017-08-10 2022-09-09 小林製薬株式会社 錠剤組成物
KR101920047B1 (ko) 2018-01-03 2018-11-19 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
KR102171141B1 (ko) * 2018-05-28 2020-10-28 중앙대학교 산학협력단 Lgi3 유래 펩타이드를 유효성분으로 포함하는 비만의 예방, 치료, 또는 개선용 조성물
CN109081862A (zh) * 2018-06-07 2018-12-25 华南理工大学 一种抗肥胖四肽pqtr及其应用
CN108676073B (zh) * 2018-06-07 2021-10-26 华南理工大学 一种抗肥胖十肽llvvypwtqr及其应用
CN112010941B (zh) * 2019-05-31 2022-08-16 华南理工大学 一种降血糖七肽
CN113248628B (zh) * 2021-07-13 2021-10-22 南京市妇幼保健院 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
KR20230046870A (ko) * 2021-09-30 2023-04-06 (주)케어젠 항비만 활성을 갖는 펩타이드 및 이의 용도
KR20230138832A (ko) 2022-03-24 2023-10-05 (주)케어젠 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도
KR20230148629A (ko) 2022-04-18 2023-10-25 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
BR9707807A (pt) * 1996-03-01 1999-07-27 Novo Nordisk As Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20020132767A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
ATE304552T1 (de) * 2000-02-18 2005-09-15 Leangene Ab Methoden zur identifizierung von zusammensetzungen, die für die behandlung von fettleibigkeit nützlich sind, unter verwendung von foxc2
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
CN100404673C (zh) * 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
CA2388287A1 (en) * 2001-05-30 2002-11-30 Terry E. Graham Therapies for the prevention and treatment of diabetes and obesity
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CN1886423A (zh) 2002-01-18 2006-12-27 普罗特米克斯公司 脂联素的糖基同工型及其用途
US20050143297A1 (en) 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
CN1980686A (zh) * 2004-04-05 2007-06-13 安斯泰来制药有限公司 抗肥胖药
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
CN101415461A (zh) * 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
WO2007102686A1 (en) 2006-03-06 2007-09-13 Caregen Co., Ltd Peptides having activities of insulin like growth factor-1 and their uses
DK2032155T3 (en) * 2006-06-09 2015-03-02 Novartis Ag Stabilized insulin-like growth factor polypeptides
CN101091765A (zh) * 2007-06-08 2007-12-26 余仁生国际有限公司 药物组合物及其预防和治疗糖尿病的用途
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
AR084558A1 (es) * 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
ES2538694T3 (es) * 2011-04-01 2015-06-23 F. Hoffmann-La Roche Ag Variantes de la T7 ARN polimerasa con sustituciones de Cisteína-Serina
KR101363455B1 (ko) * 2011-09-09 2014-02-21 (주)케어젠 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
KR20140027594A (ko) 2012-07-23 2014-03-07 씨지케이바이오 주식회사 항당뇨 및 항비만 활성을 갖는 약학 조성물
ES2704280T3 (es) 2012-09-21 2019-03-15 Dow Global Technologies Llc Método para tratar tejidos con un agente fijador de tinte
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
KR101510742B1 (ko) 2013-05-13 2015-04-10 (주)케어젠 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도
US10471125B2 (en) 2014-03-13 2019-11-12 Universite Grenoble Alpes Pharmaceutical compositions and their use for the treatment of autoimmune disorders
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CN110172083A (zh) 2019-08-27
JP6813155B2 (ja) 2021-01-13
AU2019203655B2 (en) 2020-07-02
BR122020019077B1 (pt) 2023-11-07
MX2020012993A (es) 2022-10-13
CL2019002958A1 (es) 2020-02-21
JP2020007371A (ja) 2020-01-16
CN110105432A (zh) 2019-08-09
US20190270774A1 (en) 2019-09-05
CN106459152B (zh) 2019-06-28
EP3613760A1 (en) 2020-02-26
CO2017011998A2 (es) 2018-02-09
JP2018515471A (ja) 2018-06-14
EP3613759B1 (en) 2021-07-21
IL282513B (en) 2022-01-01
ZA201708044B (en) 2022-09-28
CA3074836C (en) 2021-06-15
ES2894638T3 (es) 2022-02-15
MY197888A (en) 2023-07-23
MY197886A (en) 2023-07-23
IL255263A (en) 2018-04-30
SG10201913487RA (en) 2020-02-27
SG11201708847VA (en) 2017-11-29
US11186611B2 (en) 2021-11-30
CA3074800C (en) 2022-04-12
EP3613759A1 (en) 2020-02-26
EP3613758A1 (en) 2020-02-26
MY192154A (en) 2022-08-02
EP3290434A1 (en) 2018-03-07
US10351597B2 (en) 2019-07-16
AU2019203657A1 (en) 2019-06-13
JP2020007373A (ja) 2020-01-16
EP3613758B1 (en) 2021-07-21
US20190270773A1 (en) 2019-09-05
KR101669140B1 (ko) 2016-10-26
MX2020012994A (es) 2022-10-13
NZ737077A (en) 2019-05-31
WO2016175362A1 (ko) 2016-11-03
AU2019203657B2 (en) 2020-07-02
ES2893468T3 (es) 2022-02-09
CN110105432B (zh) 2022-12-27
MX2017013847A (es) 2018-06-15
AU2015393357A1 (en) 2017-11-30
NZ747390A (en) 2020-08-28
SA520420882B1 (ar) 2021-11-14
EP3290434B1 (en) 2020-08-19
SA517390237B1 (ar) 2021-03-17
CL2017002718A1 (es) 2018-11-09
IL282510A (en) 2021-06-30
CL2019002959A1 (es) 2020-02-21
EA037799B1 (ru) 2021-05-21
BR112017023199B1 (pt) 2023-11-07
EP3290434A4 (en) 2018-08-15
ES2831329T3 (es) 2021-06-08
AU2019203659B2 (en) 2020-07-02
IL282514B (en) 2022-01-01
JP6813156B2 (ja) 2021-01-13
CN110172083B (zh) 2022-12-30
SG10201913489UA (en) 2020-02-27
CL2019002960A1 (es) 2020-02-21
NZ747392A (en) 2020-08-28
PH12017501983B1 (en) 2018-03-19
SA520420881B1 (ar) 2023-01-15
NZ747396A (en) 2020-10-30
SA520420880B1 (ar) 2021-11-14
AU2019203659A1 (en) 2019-06-13
CA3074800A1 (en) 2016-11-03
AU2015393357B2 (en) 2019-05-16
ES2895167T3 (es) 2022-02-17
JP6908085B2 (ja) 2021-07-21
CN106459152A (zh) 2017-02-22
CA2984287A1 (en) 2016-11-03
IL255263B (en) 2022-02-01
PH12017501983A1 (en) 2018-03-19
CA2984287C (en) 2021-01-19
SG10201913490WA (en) 2020-03-30
BR112017023199A2 (pt) 2019-01-29
BR122020019171B1 (pt) 2023-11-07
EA201792365A1 (ru) 2018-04-30
IL282510B (en) 2022-01-01
US10738081B2 (en) 2020-08-11
EP3613760B1 (en) 2021-07-28
MY197887A (en) 2023-07-23
IL282513A (en) 2021-06-30
JP2020007372A (ja) 2020-01-16
AU2019203655A1 (en) 2019-06-13
US20180118783A1 (en) 2018-05-03
CA3074836A1 (en) 2016-11-03
BR122020019095B1 (pt) 2023-11-14
CA3074790C (en) 2023-01-31
US20190270772A1 (en) 2019-09-05
IL282514A (en) 2021-06-30
CA3074790A1 (en) 2016-11-03
JP6606192B2 (ja) 2019-11-13
US10626145B2 (en) 2020-04-21
HK1252251A1 (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
MX2020012994A (es) Peptido con actividad antiobesidad y antidiabetica y usos del mismo.
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX355065B (es) Método y dispositivo para conmutación de cámaras.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2014058979A3 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
EP2910563A8 (en) Triterpene derivative and its anti-influenza use
WO2016190682A3 (ko) 모루신, 구와논 지 또는 상백피를 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
PH12017500706A1 (en) Composition containing extract or fraction of genus justicia plant
WO2018093238A3 (ko) 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
BR112014003423A2 (pt) adenovirus recombinante, que compreende uma ribozima de splicing trans e um gene terapêutico do cancro, e o uso dos mesmos
EP3449920A4 (en) COMPOSITION USING NAPHTHOCHINONE - BASED COMPOUND AS ACTIVE AGENT FOR PREVENTING OR PREVENTING TEMPERATURE, CACHEXIA, PAIN, COGNITIVE DECONTAMINATION AND REDUCTION OF HEMATOPOETIC STEM CELLS AS SIDE EFFECTS RELATED TO A MEDICAMENTAL OIL CANCER TREATMENT
WO2014044869A3 (de) Medizinisches präparat umfassend einen träger mit polyhexanid oder octenidin
EP3417869A4 (en) COMPOSITION CONTAINING RHIZOMA PHRAGMITIS EXTRACT AS AN ACTIVE INGREDIENT FOR PREVENTING, IMPROVING OR TREATING DISEASES AFFECTED BY ANTI-CANCER AGENT'S SECONDARY EFFECT
IN2015MN00091A (es)
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.
WO2014031034A8 (ru) Фармацевтические композиции, содержащие ипидакрин и их применение для лечения нарушений потенции и других форм половой активности
EA201892048A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения
TH1701006471A (th) เพปไทด์ที่มีสภาพออกฤทธิ์แก้โรคอ้วนและแก้โรคเบาหวานตลอดจนการใช้เพปไทด์ ดังกล่าว
TH166182B (th) "สารผสมทางเภสัชกรรมสำหรับการป้องกันหรือบำบัดรักษาผื่นผิวหนัง"
MY182607A (en) Combination composition, comprising as active ingredients l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency